Base Editing (BE4max) for FOXG1 c.632T>C (p.Ile211Thr) in FOXG1 syndrome

Base Editing (BE4max) via AAV9 delivery is a rationale-driven therapeutic strategy for FOXG1 syndrome targeting the FOXG1 c.632T>C (p.Ile211Thr) variant (Pathogenic, missense variant). The editing system (BE4max (cytosine base editor)) converts the pathogenic C to T (or G to A on the target strand), restoring the wild-type codon. Target tissue: CNS. Therapeutic goal: Correct FOXG1 haploinsufficiency at the CNS FOXG1 locus to restore near-normal FOXG1 function and improve neurodevelopmental outcomes.. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: FOXG1 NM_005249.5(FOXG1):c.632T>C (p.Ile211Thr) is classified as Pathogenic (ClinVar variation ID 979179). Molecular consequence: missense variant. Protein change: I211T. 2. Epidemiology: Ultra-rare neurodevelopmental disorder with several hundred to a few thousand diagnosed individuals worldwide; onset in neonatal/infant period with profound, lifelong disability and global distribution concentrated in tertiary pediatric neurology/genetics centers. 3. Standard of care: Purely symptomatic and supportive: anti-seizure medications, management of movement disorders and spasticity, feeding support (often gastrostomy), reflux and respiratory management, orthopedic and ophthalmologic care, and intensive developmental and educational interventions. No approved disease-mod 4. Pipeline: One active Phase 1/2 AAV9 gene replacement trial (FRF-001, NCT07293546) with orphan and Rare Pediatric Disease designations; additional preclinical AAV9-FOXG1 programs in mouse models demonstrating structural and functional rescue. No registered ASO or CRISPR/base-editing clinical trials yet; other 5. CBE clinical validation: BE4max (Koblan et al. 2018) is the gold-standard cytosine base editor. Multiple CBE programs are in clinical development for liver and hematologic targets.

1. No published data specifically correcting FOXG1 c.632T>C (p.Ile211Thr) with Base Editing (BE4max); strategy is based on general principles and must be validated preclinically.
2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed.
3. Delivery to CNS tissue remains a major translational bottleneck. Current vectors have limited transduction efficiency in these compartments.
4. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.